Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

Natera said it has acquired Foresight Diagnostics in a deal valued at up to $450 million, bolstering the company's portfolio of minimal residual disease, or MRD, testing products.

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Quest Diagnostics, a cancer treatment laboratory in Lewisville, received a proclamation from Lewisville City Council after ...

The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing ...

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma. This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.

Natera ( ($NTRA) ) just unveiled an update. On December 4, 2025, Natera, Inc. completed its acquisition of Foresight Diagnostics, a cancer ...